The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
ACADEMIA
Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
US medical journal Hypertension has published a letter by a Japanese cardiologist, in which he brought up statistical concerns over the CASE-J study, a large-scale clinical trial that compared the angiotensin receptor blocker candesartan and the calcium channel blocker amlodipine.…
To read the full story
Related Article
- Takeda Submits Plans to Improve Business Practices
July 13, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
ACADEMIA
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…